Yes, lets start the trial. Here is the paper RP

Quote:

---

Survival data from the MARACON trial is not conclusive due to the limited number of patients and the much more unfavorable clinical features of these patients compared with typical patient cohorts on fourth- or fifth-line therapy (Grothey et al., 2013). Looking at the trial data, it is nevertheless clear that the subsequent objective treatment responses are very encouraging. Historically the objective response rates in patients on or after the third line of chemotherapy are around 5%–10% (Nielsen et al., 2014).No large datasets exist on patients on or after fourth-line therapy, but objective responses were generally not observed and chemotherapy is only applied for symptom control (Arkenau et al., 2009). This is in contrast to our result of a high response rate in this advanced situation.

---